AI Summary
✦ ClarthaFortis Healthcare is an Indian hospital and healthcare delivery company, generating revenue from cardiac sciences, oncology, and nephrology services. It also operates critical care, emergency and trauma, and transplant-focused facilities. Q1 FY27 revenue increased 17%, while profit rose 35%, with improving margins indicating operating leverage across its hospital network. Debt/equity of 34.15 implies extreme leverage, making ROE unavailable and increasing financial risk despite margin expansion. Earnings growth currently exceeds revenue growth, suggesting better cost absorption and service mix. At 69.5 times earnings, Fortis appears rich relative to its growth rate, leaving valuation exposed to execution, leverage, and sustained margin improvement.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 20 analysts
Fundamentals
Fundamentals institutional score is 48 using growth durability 48.3.
Valuation
Valuation institutional score is 27 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 80 using mean target upside 19.8%; dispersion penalty 7.8; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 51 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 11 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. analyst consensus and market sentiment provide support, while fundamentals and valuation remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 43.1% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +1.18). Confidence: 67%.
Live forward EPS implies next-12-month EPS of ₹22.79. Applying the stock's normalized valuation corridor produces a fair range of ₹753.89 to ₹1,500.49, with base value near ₹1,090.05 (+17.0% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹22.79
Forward P/E
40.9x
Base Fair Value
₹1,090.05
Fair Range
₹753.89 - ₹1,500.49
Upside To Base
+17.0%
Estimate Source
Live forward EPS
Growth Estimate
+2.3%
5Y Average
38.38
Current
68.43
Overvalued
65.84
Undervalued
33.08
5Y Average
20.74
Current
36.98
Overvalued
29.26
Undervalued
11.09
5Y Average
4.15
Current
7.40
Overvalued
5.85
Undervalued
2.22
Peers & Comparison
Sector: Health Care · Theme: Hospitals & Diagnostic Centres
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
NARAYANA HRUDAYALAYA LTD. NHHospitals & Diagnostic Centres | +80.4% | 9.0% | 45.3x Undervalued | -44% vs avg | +6.8% |
GLOBAL HEALTH LIMITED MEDANTAHospitals & Diagnostic Centres | +26.5% | 11.9% | 71.4x Fair | -11% vs avg | +4.9% |
ASTER DM QUALITY CARE LTD ASTERDMHospitals & Diagnostic Centres | +21.6% | 6.5% | 140.5x Premium | +75% vs avg | +47.9% |
DR. LAL PATH LABS LTD. LALPATHLABHospitals & Diagnostic Centres | +19.1% | 18.7% | 60.2x Undervalued | -25% vs avg | +20.0% |
RAINBOW CHILDRENS MED LTD RAINBOWHospitals & Diagnostic Centres | +33.2% | 15.7% | 54.6x Undervalued | -32% vs avg | +3.5% |
VIJAYA DIAGNOSTIC CEN LTD VIJAYAHospitals & Diagnostic Centres | +26.6% | 21.2% | 83.1x Fair | +4% vs avg | +28.7% |
DR AGARWALS HEALTH CARE L AGARWALEYEHospitals & Diagnostic Centres | +26.0% | 6.7% | 120.8x Premium | +51% vs avg | +22.4% |
APOLLO HOSPITALS ENTER. L APOLLOHOSPHospitals & Diagnostic Centres | +18.1% | 7.7% | 66.0x Undervalued | -18% vs avg | +23.2% |
FORTIS HEALTHCARE LTD trades in line with peers (68.7x vs avg 80.2x), reflecting a fair valuation within the Hospitals & Diagnostic Centres cohort. Peers include NARAYANA HRUDAYALAYA LTD., GLOBAL HEALTH LIMITED, ASTER DM QUALITY CARE LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹489 CrJun 2026Latest net profit
₹48 CrJun 2026Latest EPS
₹0.63Jun 2026Net margin
21.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 289 | 294 | 291 | 307 | 333 | 357 | 367 | 388 | 433 | 456 | 443 | 461 | 489 |
| Expenses + | 254 | 255 | 242 | 238 | 275 | 297 | 300 | 318 | 345 | 356 | 344 | 350 | 386 |
| Operating Profit | 35 | 40 | 49 | 69 | 58 | 60 | 67 | 71 | 88 | 100 | 99 | 110 | 104 |
| OPM % | 12% | 13% | 17% | 23% | 17% | 17% | 18% | 18% | 20% | 22% | 22% | 24% | 21% |
| Other Income + | 31 | 110 | 32 | 65 | 35 | 36 | 40 | -27 | 57 | 114 | 21 | 4 | 32 |
| Interest | 23 | 21 | 19 | 18 | 17 | 16 | 27 | 52 | 52 | 51 | 56 | 48 | 47 |
| Depreciation | 25 | 25 | 25 | 26 | 26 | 27 | 29 | 31 | 30 | 28 | 30 | 30 | 30 |
| Profit before tax | 18 | 104 | 36 | 90 | 50 | 52 | 51 | -39 | 63 | 135 | 34 | 37 | 59 |
| Tax % | 27% | 8% | 36% | 24% | 47% | 24% | 22% | 9% | 18% | 7% | 17% | 33% | 19% |
| Net Profit + | 13 | 95 | 23 | 68 | 27 | 40 | 40 | -42 | 52 | 125 | 28 | 25 | 48 |
| EPS in Rs | 0.17 | 1.26 | 0.30 | 0.91 | 0.36 | 0.52 | 0.52 | -0.56 | 0.69 | 1.66 | 0.38 | 0.33 | 0.63 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome